DOCSLIB.ORG

Β Blockers Timolol Betaxolol Carteolol Ocular Hypotensives: List The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Β Blockers Timolol Betaxolol Carteolol Ocular Hypotensives: List The 1 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 2 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 3 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) An FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 4 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 5 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three Zioptan (and that’s all we’ll have to say about it) (Latanaprostene bunod) A PGA combo drug 6 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three Zioptan (and that’s all we’ll have to say about it) (Latanaprostene bunod) A PGA combo drug 7 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of latanaprostene bunod? (Tafluprost) agonist An FDA-approvedVyzulta PGA, much less well-known than the big three (Latanaprostene bunod) A PGA combo drug (We’ll have more to say about this drug shortly) 8 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of latanaprostene bunod? (Tafluprost) agonist An FDA-approvedVyzulta PGA, much less well-known than the big three (Latanaprostene bunod) A PGA combo drug (We’ll have more to say about this drug later) 9 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin 10 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin 11 Ocular Hypotensives: List the common agents blockers Timolol (This drove me nuts when I was a med Betaxolol student—how could the same disease be Carteolol treated by two different medicines with the Prostaglandin analogues exact opposite effect? The first time I read it, Latanaprost I assumed it was a typo.) Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin 12 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI (carbonic anhydrase inhibitors) Dorzolamide Brinzolamide Acetazolamide 13 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide 14 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide There is another, less well-known CAI—what is it? ?df 15 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide There is another, less well-known CAI—what is it? Methazolamidedf Methazolamide 16 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine 17 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine 18 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo 19 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilocarpine (Pilo for short) 20 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor 21 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor Netarsudil 22 Q Ocular Hypotensives: List the common agents blockers Brand Name? Timolol Timoptic Betaxolol xxxxx Carteolol xxxxx Prostaglandin analogues Latanaprost Xalatan Travaprost Travatan Bimataprost Lumigan Nonselective agonist These meds are rarely used anymore (except for Epinephrine xxxxx pilo in certain situations), Dipivefrin xxxxx so we won’t bother with their brand names CAI Dorzolamide Trusopt Brinzolamide Azopt Acetazolamide Diamox Selective agonists Apraclonidine Iopidine Brimonidine Alphagan Miotics Pilo xxxxx Rho kinase inhibitor Netarsudil 23 A Ocular Hypotensives: List the common agents blockers Brand Name? Timolol Timoptic Betaxolol xxxxx Carteolol xxxxx Prostaglandin analogues Latanaprost Xalatan Travaprost Travatan Bimataprost Lumigan Nonselective agonist Epinephrine xxxxx Dipivefrin xxxxx CAI Dorzolamide Trusopt Brinzolamide Azopt Acetazolamide Diamox Selective agonists Apraclonidine Iopidine Brimonidine Alphagan Miotics Pilo xxxxx Rho kinase inhibitor Netarsudil Rhopressa 24 Q Ocular Hypotensives: List the common agents blockers Timolol What is the name of the equation that Betaxolol describes the factors determining IOP? Carteolol Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor Netarsudil 25 A Ocular Hypotensives: List the common agents blockers Timolol What is the name of the equation that Betaxolol describes the factors determining IOP? Carteolol The Goldmann equation Prostaglandin analogues Latanaprost Travaprost Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor Netarsudil 26 Q Ocular Hypotensives: List the common agents blockers Timolol What is the name of the equation that Betaxolol describes the factors determining IOP? Carteolol The Goldmann equation Prostaglandin analogues Latanaprost What is the Goldmann equation? (Meaning, Travaprost write it out) Bimataprost Nonselective agonist Epinephrine Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor Netarsudil 27 A Ocular Hypotensives: List the common agents blockers Timolol What is the name of the equation that Betaxolol describes the factors determining IOP? Carteolol The Goldmann equation Prostaglandin analogues Latanaprost What is the Goldmann equation? (Meaning, Travaprost write it out) Bimataprost Rate of aqueous formation Nonselective agonist IOP = + EVP Epinephrine Rate of aqueous outflow Dipivefrin CAI Dorzolamide Brinzolamide Acetazolamide Selective agonists Apraclonidine Brimonidine Miotics Pilo Rho kinase inhibitor Netarsudil 28 Q Ocular Hypotensives: List the common agents blockers Timolol What is the name of the equation that Betaxolol describes
Load more

Recommended publications
  • The Effect of Topical Beta-Adrenoceptor Blocking Agents on Pulsatile Ocular Blood Flow
    THE EFFECT OF TOPICAL BETA-ADRENOCEPTOR BLOCKING AGENTS ON PULSATILE OCULAR BLOOD FLOW C. D. MORSMAN, M. E. BOSEM, M. LUSKY and R. N. WEINREB San Diego, California SUMMARY factors (e.g. hypertension, diabetes, peripheral Thirty-three ocular hypertensive patients (21 with vascular disease and vasospasm) to the vascular primary open angle glaucoma and 12 glaucoma system suggest that blood flow in the optic nerve suspects) were randomly assigned to receive either head and retina may be altered in glaucoma.4 Of the timolol, levobunolol or betaxolol in one eye. Pulsatile various vascular beds within the posterior segment, ocular blood flow (POBF) was measured before the choroidal circulation is of particular interest since treatment (baseline) and 2 hours after drop adminis­ it provides the major contribution to the blood flow tration. After 1 week of regular twice-daily dosage, of the optic nerve at the level of the lamina cribrosa.5 POBF was measured again both immediately before Beta-2 adrenergic receptors have been demon­ and 2 hours after drop instillation. All measurements strated in human optic nerve,6 as well as in choroidal were made by an investigator masked to treatment. and retinal blood vessels.7 Blockade of these POBF increased by 11% (p = 0.09) at week 0 after receptors can cause vasoconstrictionS which could levobunolol administration, and by 22% (p = 0.20) at adversely affect visual function if adequate concen­ week 1 before drop administration compared with trations of the drug diffused into the posterior baseline. It dropped by 23% and 25% (p = 0.04 and segment of the eye or were absorbed systemically.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • Use of Emulsions for Intra- and Periocular Injection
    (19) & (11) EP 1 611 879 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/107 (2006.01) 12.08.2009 Bulletin 2009/33 (21) Application number: 04291684.1 (22) Date of filing: 02.07.2004 (54) Use of emulsions for intra- and periocular injection Verwendung von Emulsionen zur intra- und periocularen Injection Utilisation des émulsions pour injection intra- et périoculaire. (84) Designated Contracting States: (74) Representative: de Mareüil-Villette, Caroline et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cabinet Plasseraud HU IE IT LI LU MC NL PL PT RO SE SI SK TR 52 rue de la Victoire 75440 Paris Cedex 09 (FR) (43) Date of publication of application: 04.01.2006 Bulletin 2006/01 (56) References cited: EP-A- 0 521 799 EP-A- 1 020 194 (73) Proprietors: WO-A-02/09667 WO-A-93/18852 • Novagali Pharma S.A. WO-A-94/05298 WO-A-03/053405 91000 Evry (FR) US-A- 5 632 984 • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) • KLANG S H ET AL: "PHYSICOCHEMICAL 75016 Paris (FR) CHARACTERIAZATION AND ACUTE TOXICITY • INSTITUT NATIONAL DE LA SANTE ET DE LA EVALUATION OF A POSITIVELY-CHARGED RECHERCHE MEDICALE (INSERM) SUBMICRON EMULSION VEHICLE" JOURNAL 75013 Paris (FR) OF PHARMACY AND PHARMACOLOGY, • YISSUM RESEARCH DEVELOPMENT COMPANY LONDON, GB, vol. 46, no. 12, December 1994 OF THE HEBREW UNIVERSITY OF JERUSALEM (1994-12), pages 986-993, XP008005426 ISSN: 91390 Jerusalem (IL) 0022-3573 • KLANG S ET AL: "INFLUENCE OF EMULSION (72) Inventors: DROPLET SURFACE CHARGE ON • Rabinovich-Guilatt, Laura INDOMETHACIN OCULAR TISSUE 75015 Paris (FR) DISTRIBUTION" PHARMACEUTICAL • De Kozak, Yvonne DEVELOPMENT AND TECHNOLOGY, NEW 75013 Paris (FR) YORK, NY, US, vol.
    [Show full text]
  • Fluid Ophthalmic Composition Based on Lipid Microparticles Containing at Least One Active Principle
    Europaisches Patentamt J European Patent Office Office europden des brevets (11) Publication number : 0 437 368 A1 EUROPEAN PATENT APPLICATION (21) Application number: 91300181.4 ® int. ci.5 : A61K 9/06, A61K 9/16 @ Date of filing : 10.01.91 © Priority : 12.01.90 FR 9000340 (72) Inventor : Rozier, Annouk 23 Bd Lafayette F-63000 Clermont-Ferrand (FR) @ Date of publication of application : 17.07.91 Bulletin 91/29 74) Representative : Hesketh, Alan, Dr. et al European Patent Department Merck & Co., @ Designated Contracting States : Inc. Tertings Park Eastwick Road CH DE FR GB IT LI NL Harlow Essex, CM20 2QR (GB) © Applicant : LABORATOIRES MERCK, SHARP & DOHME-CHIBRET 3, Avenue Hoche F-75008 Paris (FR) (S) Fluid ophthalmic composition based on lipid microparticles containing at least one active principle. (57) There is described a fluid ophthalmic composition which comprises a suspension in a fluid dispersant medium of lipid microparticles containing at least one active principle. The composition enables improved availability of the active principle to be obtained as a result of high intraocular levels. 00 <0 CO Q. UJ Jouve, 18, rue Saint-Denis, 75001 PARIS EP 0 437 368 A1 FLUID OPHTHALMIC COMPOSITION BASED ON LIPID MICROPARTICLES CONTAINING AT LEAST ONE ACTIVE PRINCIPLE The present invention relates to a fluid ophthalmic composition. Many ophthalmic compositions are currently available in liquid or solid form, but none of them is, in fact, completely satisfactory. In effect, liquid ophthalmic compositions, although easy to use, have some drawbacks ; in particular, it is 5 difficult to obtain a sustained or delayed action of the active principle which they contain.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (Apraclonidine Hydrochloride) Eye Drops 0.5%
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (apraclonidine hydrochloride) Eye Drops 0.5%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of Iopidine Eye Drops 0.5% contains apraclonidine hydrochloride 5.75 mg, equivalent to apraclonidine base 5 mg. Excipient with known effect Benzalkonium chloride 0.1 mg per 1 mL as a preservative. For the full list of excipients, see section 6.1. 2. PHARMACEUTICAL FORM Eye drops, solution, sterile, isotonic. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Iopidine Eye Drops 0.5% are indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with Iopidine Eye Drops 0.5% to delay surgery should have frequent follow up examinations and treatment should be discontinued if the intraocular pressure rises significantly. The addition of Iopidine Eye Drops 0.5% to patients already using two aqueous suppressing drugs (i.e. beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine is an aqueous-suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP-lowering efficacy of Iopidine Eye Drops 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month. 4.2. Dose and method of administration Dose One drop of Iopidine Eye Drops 0.5% should be instilled into the affected eye(s) three times per day.
    [Show full text]
  • Canine Red Eye Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO
    PEER REVIEWED Clinical Approach to the CANINE RED EYE Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO he acute red eye is a common clinical challenge for tion of the deep episcleral vessels, and is characterized general practitioners. Redness is the hallmark of by straight and immobile episcleral vessels, which run Tocular inflammation; it is a nonspecific sign related 90° to the limbus. Episcleral injection is an external to a number of underlying diseases and degree of redness sign of intraocular disease, such as anterior uveitis and may not reflect the severity of the ocular problem. glaucoma (Figures 3 and 4). Occasionally, episcleral Proper evaluation of the red eye depends on effective injection may occur in diseases of the sclera, such as and efficient diagnosis of the underlying ocular disease in episcleritis or scleritis.1 order to save the eye’s vision and the eye itself.1,2 • Corneal Neovascularization » Superficial: Long, branching corneal vessels; may be SOURCE OF REDNESS seen with superficial ulcerative (Figure 5) or nonul- The conjunctiva has small, fine, tortuous and movable vessels cerative keratitis (Figure 6) that help distinguish conjunctival inflammation from deeper » Focal deep: Straight, nonbranching corneal vessels; inflammation (see Ocular Redness algorithm, page 16). indicates a deep corneal keratitis • Conjunctival hyperemia presents with redness and » 360° deep: Corneal vessels in a 360° pattern around congestion of the conjunctival blood vessels, making the limbus; should arouse concern that glaucoma or them appear more prominent, and is associated with uveitis (Figure 4) is present1,2 extraocular disease, such as conjunctivitis (Figure 1).
    [Show full text]
  • Drug List (SORTED by TRADE with GENERIC EQUIVALENT)
    NBEO Drug List (SORTED BY TRADE WITH GENERIC EQUIVALENT) Trade Generic Trade Generic Abilify aripiprazole Avandia rosiglitazone Accolate zafirlukast Avastin bevacizumab Accupril quinapril Azasan azathioprine Achromycin tetracycline AzaSite azithromycin Aciphex rabeprazole Avodart dutasteride Actos pioglitazone Azopt brinzolamide Acular ketorolac Bactrim trimethoprim-sulfamethoxazole Acuvail ketorolac Bactrim DS trimethoprim-sulfamethoxazole Advair fluticasone propionate Baquacil polyhexamethylene biguanide Advil ibuprofen Beconase AQ beclomethasone AeroBid flunisolide Benadryl diphenhydramine Afrin oxymetazoline Bepreve Bepotastine besilate Aggrenox aspirin and dipyridamole Besivance besifloxacin Alamast pemirolast Betadine povidone-iodine Alaway ketotifen Betagan levobunolol Aldactone spironolactone Betasept chlorhexidine topical Aleve naproxen sodium Betaseron interferon beta-1b Allegra fexofenadine Betimol timolol Allegra-D fexofenadine-pseudoephedrine Betoptic S betaxolol Alluvia lopinavir Biopatch chlorhexidine topical Alocril nedocromil Blephamide sulfacetamide-prednisolone Alomide lodoxamide Botox onabotulinum toxinA Alphagan P brimonidine Brolene propamidine isethionate Alrex loteprednol 0.2% Bromday bromfenac Ambien zolpidem Calamine zinc oxide and iron oxide Amicar aminocaproic acid Calan verapamil Amoxil amoxicillin Calgon Vesta chlorhexidine topical Amphocin amphotericin B Capoten captopril Anectine succinylcholine Carafate sucralfate Ansaid flurbiprofen Carbocaine mepivacaine HCl injection Antivert meclizine Cardizem diltiazem
    [Show full text]
  • NEW CONCEPTS in GLAUCOMA CARE TREATMENT Proceedings of the Fifteenth Annual Meeting & of the Optometric Glaucoma Society
    NEW CONCEPTS IN GLAUCOMA CARE TREATMENT Proceedings of the Fifteenth Annual Meeting & of the Optometric Glaucoma Society INSIDE: • Virtual Reality Uses in Glaucoma • Questions Glaucoma Patients Ask • Pathogenesis of Glaucoma • Glaucoma Progression • Real-Time Aqueous Humor Outfl ow Imaginging APRIL 2017 REVIEW OF OPTOMETRY/APRIL 2017 1 0217_OGS_ja_3.22.indd 1 3/24/17 3:36 PM ro0417ogs_vyzulta.indd 1 3/20/17 1:57 PM NEW CONCEPTS IN GLAUCOMA CARE TREATMENT TABLE OF CONTENTS INTRODUCTORY REMARKS The 15th Annual Scientifi c Meeting of the Optometric Glaucoma Society (OGS), held Nov. 15 and 16, 2016, in Anaheim, Calif., brought 3 together some of the country’s top luminaries INTRODUCTORY REMARKS in the areas of glaucoma diagnosis, treatment, Highlights From the Annual Scientifi c assessment, and management. These individu- Meeting als shared groundbreaking research and the BY MURRAY FINGERET, OD latest clinical knowledge about glaucoma—con- sidered to be the top global eye burden by the World Health Organization. 4 Kicking things off in the President’s Lecture, PRESIDENT’S LECTURE Felipe A. Medeiros, MD, PhD, highlighted potential clinical applications for More Than a Video Game: Virtual virtual reality devices. These devices, being tested in simulation laboratories, Reality and Its Uses in Glaucoma could one day assist clinicians in assessing patients at risk for glaucoma and BY FELIPE A. MEDEIROS, MD, PHD in danger of falls and motor vehicle accidents due to visual fi eld loss. Make no mistake: These cutting-edge tools are not your techie’s virtual reality. Dr. Medeiros, in a separate lecture about glaucoma progression, unveiled 6 an innovative metric developed by his research group to measure functional PATIENT CARE and structural vision loss in glaucoma patients.
    [Show full text]
  • IOPIDINE® 0.5% (Apraclonidine Ophthalmic Solution) 0.5% As Base
    IOPIDINE® 0.5% (apraclonidine ophthalmic solution) 0.5% As Base DESCRIPTION: IOPIDINE® 0.5% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha adrenergic agonist, in a sterile isotonic solution for topical application to the eye. Apraclonidine hydrochloride is a white to off-white powder and is highly soluble in water. Its chemical name is 2-[(4-amino-2,6 dichlorophenyl) imino]imidazolidine monohydrochloride with an empirical formula of C9H11Cl3N4 and a molecular weight of 281.57. The chemical structure of apraclonidine hydrochloride is: Each mL of IOPIDINE 0.5% Ophthalmic Solution contains: Active: apraclonidine hydrochloride 5.75 mg equivalent to apraclonidine base 5 mg; . Inactives: sodium chloride, sodium acetate, sodium hydroxide and/or hydrochloric acid (pH 4.4-7.8), purified water and benzalkonium chloride 0.01% (preservative) CLINICAL PHARMACOLOGY: Apraclonidine hydrochloride is a relatively selective alpha- 2-adrenergic agonist. When instilled in the eye, IOPIDINE 0.5% Ophthalmic Solution, has the action of reducing elevated, as well as normal, intraocular pressure (IOP), whether or not accompanied by glaucoma. Ophthalmic apraclonidine has minimal effect on cardiovascular parameters. Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. IOPIDINE 0.5% Ophthalmic Solution has the action of reducing IOP. The onset of action of apraclonidine can usually be noted within one hour, and maximum IOP reduction occurs about three hours after instillation. Aqueous fluorophotometry studies demonstrate that apraclonidine's predominant mechanism of action is reduction of aqueous flow via stimulation of the alpha-adrenergic system.
    [Show full text]